To assess the cutoff value for detecting circulating methylated GCM2 and TMEM240 in plasma for predicting tumor progression, we employed a training group comprising 14 Eastern European and 152 Taiwanese breast cancer patients. This evidence concerns the gene TMEM240 and breast cancer.